Literature DB >> 27197625

Anticoagulants: What is new and what is the standard?

L J Lesko1.   

Abstract

This commentary focuses on the status of oral anticoagulants, namely, warfarin and the novel oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban.
© 2016 ASCPT.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27197625     DOI： 10.1002/cpt.400

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  3 in total

Review 1.  Biomimetic nanoparticle technology for cardiovascular disease detection and treatment.

Authors:  Joon Ho Park; Diana Dehaini; Jiarong Zhou; Maya Holay; Ronnie H Fang; Liangfang Zhang
Journal:  Nanoscale Horiz       Date:  2019-06-28       Impact factor: 10.989

2.  The impact of R353Q genetic polymorphism in coagulation factor VII on the initial anticoagulant effect exerted by warfarin.

Authors:  Chanan Shaul; Simcha Blotnick; Liat Deutsch; Gilad Rosenberg; Yoseph Caraco
Journal:  Eur J Clin Pharmacol       Date:  2018-11-09       Impact factor: 2.953

3.  Critical Quality Control Methods for a Novel Anticoagulant Candidate LFG-Na by HPSEC-MALLS-RID and Bioactivity Assays.

Authors:  Shunliang Zheng; Yi Wang; Jiashuo Wu; Siyao Wang; Huaifu Wei; Yongchun Zhang; Jianbo Zhou; Yue Shi
Journal:  Molecules       Date:  2022-07-15       Impact factor: 4.927
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.